Healthcare CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, healthcare CDMO market size in 2026 is estimated at USD 363.21 billion, growing from 2025 value of USD 331.22 billion with 2031 projections showing USD 576.26 billion, growing at 9.66% CAGR over 2026-2031.

This report is Segmented by Service Type (Contract Development, Contract Manufacturing), Development Phase (Pre-Clinical, Phase I, and More), Therapeutic Area (Oncology, Cardiovascular, and More), End User (Big/Large Pharmaceutical Companies, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Healthcare CDMO Market Trends and Insights

Mainstream Outsourcing to Focus on Core Competencies

Rising research intensity and finite internal resources have pushed 86.9% of originators to outsource at least one manufacturing activity. Portfolio simplification enables sponsors to redeploy capital toward discovery while transferring fixed-asset risk to capable partners. Lonza's USD 1.2 billion Vacaville acquisition, paired with the sale of its capsules unit, exemplifies the pivot toward high-value biologics focus. Large pharma is simultaneously divesting small-molecule plants, redirecting attention to first-in-class biologics and mRNA platforms. CDMOs benefit through multiyear master service agreements that underpin utilization planning and unlock cross-selling for analytical, regulatory, and fill-finish add-ons.

Growth in Biologics & Advanced Therapies

Monoclonal antibodies, antibody-drug conjugates (ADCs), cell, and gene therapies require cleanroom designs, containment protocols, and supply-chain orchestration few originators deem economical in-house. The FDA's Advanced Manufacturing Technologies Designation Program finalized in 2025 further encourages novel production models, reducing approval risk for CDMOs that deploy innovative equipment. Capital intensity for viral vector suites and segregated high-potency lines drives sponsors to partner earlier, often during pre-clinical formulation. As commercial approvals of CAR-T and gene-edited products climb, so does demand for small-lot, just-in-time manufacturing and end-to-end logistics solutions that preserve cell viability.

Capacity Constraints & Long CDMO Lead-Times

Even aggressive expansion has not fully met the surge in biologics outsourcing. Allocation windows for specialized ADC suites run 24-36 months, forcing sponsors to secure slots before Phase I readouts. Daiichi Sankyo's USD 1 billion German ADC plant and AstraZeneca's USD 1.5 billion project in Singapore will relieve pressure only from 2028 onward. The mismatch elevates negotiation leverage of integrated CDMOs and increases reservation fees, yet also spurs clients to pursue dual-sourcing or retain pilot capacity to protect timelines.

Other drivers and restraints analyzed in the detailed report include:

1. Increasing Molecule Complexity Demanding End-to-End CDMOs
2. AI-Driven Process Optimization Slashing Tech-Transfer Timelines
3. Stringent Compliance / Audit Failures

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Contract Manufacturing held 73.45% of healthcare contract development and manufacturing organization market share in 2025 because large pharma historically retained formulation expertise while outsourcing volume production. The sub-segment spans small-molecule APIs, monoclonal antibody titers exceeding 15,000 L, and sterile injectables, each carrying distinct margin profiles. Demand for high-potency and cytotoxic suites pushes average selling price upward and commands multi-year take-or-pay agreements. In contrast, commoditized oral solids see price compression but still underpin line utilization.

Contract Development is forecast to post a 10.44% CAGR, reflecting earlier third-party involvement in pre-formulation, process characterization, and regulatory dossier assembly. Sponsors favor a single knowledge continuum from laboratory to commercial scale, which reduces validation repetition and eases change-control filings. The healthcare contract development and manufacturing organization market therefore sees hybrid contracts where a development retainer rolls into commercial supply options, aligning incentives for rapid technology transfer. As ADCs, vector-based vaccines, and personalized therapies proliferate, process knowledge becomes inseparable from late-stage manufacturing, blurring traditional boundaries between development and production services.

Commercial and Post-Approval programs represented 39.35% of healthcare contract development and manufacturing organization market size in 2025, anchoring predictable revenue streams tied to approved molecules. Lifecyle-management activities such as formulation optimization or new dosage strengths sustain volumes beyond patent expiry. Price ceilings exist, yet high-margin biologics continue to offset commoditized mature brands.

Phase I work is expected to climb at 10.78% CAGR to 2031 as emerging modalities require specialized toxicology batches and flexible cleanrooms. Sponsors engage CDMOs before first-in-human dosing to hedge internal skill gaps around viral vector cGMP or mRNA encapsulation. Earlier engagement yields longer total contract duration and often positions the same partner for later commercial supply, enlarging the addressable healthcare contract development and manufacturing organization market size over the product life cycle. Phase II and III volumes grow steadily but face scheduling volatility tied to clinical success, prompting CDMOs to diversify client rosters to balance attrition risk.

Complete Report Scope:

• By Service Type
  • Contract Development
    • Pre-formulation & Formulation Development
    • Process Development & Optimisation
    • Analytical, Stability & Release Testing
  • Contract Manufacturing
    • API Manufacturing
      • Small-molecule APIs
        • Monoclonal Antibodies
      • Large-molecule / Biologic APIs
        • Recombinant Proteins
    • Finished Dosage Formulation
      • Vaccines
      • Oral Solids (Tablets, Capsules)
        • Cell & Gene Therapies
      • Sterile Injectables / Fill-Finish
      • Topicals & Semi-solids
      • Other Dosage Forms
    • Packaging & Serialization Services
    • Medical Devices
      • Class I
      • Class II
      • Class III
• By Therapeutic Area
  • Oncology
  • Cardiovascular
  • Infectious Diseases
  • Neurology / CNS
  • Auto-immune & Inflammatory
  • Metabolic Disorders (Diabetes, Obesity)
  • Rare & Orphan Diseases
  • Other Therapeutic Areas
• By Development Phase
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Commercial / Post-Approval
• By End User
  • Big / Large Pharmaceutical Companies
  • Emerging & Virtual Biotech Firms
  • Generic Drug Manufacturers
  • Medical-Device & Combination-Product Firms
  • Academic, Government & Non-Profit Sponsors
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America held 41.75% of 2025 revenue, anchored by FDA familiarity, established cold-chain logistics, and concentrated sponsor headquarters. Recent capacity announcements in Syracuse and Kentucky target high-potency and sterile injectables, reflecting the region's pivot to complex biologics rather than cost-sensitive APIs. Despite rising labor and utility costs, proximity to innovation hubs and seasoned regulatory talent keeps first-in-human and launch production onshore.

Asia-Pacific is set to post an 11.57% CAGR to 2031, driven by scale-up grants in China, Singapore, and South Korea. Government incentives lower capital hurdles for GMP suites, while competitive wages widen the cost differential with trans-Atlantic peers. Samsung Biologics added 360,000 L of capacity across Plants 4 and 5 and secured a USD 1.4 billion multi-product deal in early 2025. The region's challenge remains regulatory harmonization, yet recent alignment with ICH guidelines has improved sponsor confidence.

Europe occupies a middle ground, pairing stringent quality culture with attractive R&D tax frameworks. Switzerland, Ireland, and Germany dominate high-value biologics, exemplified by Lonza's ADC expansion in Visp. Eastern European sites cater to oral dose and sterile packaging at competitive rates. South America and Middle East & Africa still represent single-digit shares but win investment as part of geopolitical diversification and pandemic supply-chain resilience strategies.

1. Catalent
2. Lonza Group
3. Thermo Fisher Scientific
4. Samsung Biologics Co., Ltd.
5. WuXi AppTec Co., Ltd.
6. FUJIFILM
7. Baxter
8. Cambrex
9. PCI Pharma Services (PCI Services LLC)
10. Recipharm
11. AGC Inc.
12. Jubilant Pharmova Limited
13. Piramal Pharma Limited
14. Abbvie
15. C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim)
16. Vetter Pharma-Fertigung GmbH & Co. KG
17. Delpharm SAS
18. Fareva S.A.
19. Siegfried Holding AG

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support